Arbutus Biopharma Corp
NASDAQ:ABUS
Relative Value
The Relative Value of one
ABUS
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 3.97 USD,
Arbutus Biopharma Corp
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ABUS Competitors Multiples
Arbutus Biopharma Corp Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
762.1m USD | 52.2 | -18 | -20.1 | -19.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.4B USD | 6.7 | 171.4 | 16.6 | 23.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
199.5B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.8B USD | 6.5 | 23.3 | 15.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.5B USD | 10.1 | 32.3 | 23.7 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.8B USD | 5.8 | 18.5 | 14 | 16 | |
| AU |
|
CSL Ltd
ASX:CSL
|
72.7B AUD | 3.3 | 16.8 | 11.5 | 14.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.2 | 33.4 | 57 | 58.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |